Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06223607 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Aug 22, 2024 to Dec 28, 2026
    • Study completion date: Aug 22, 2024 to Dec 22, 2027
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).
Trial Details
NCT Number NCT06223607
Lead Sponsor Methodist Health System
Conditions
(from sponsor)		 Baseline Thrombocytopenia
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov